Summary.Acetylator status was determined in 112 normal and 116 diabetic subjects. Forty-eight percent of the normal subjects were fast acetylators compared with 74% of the Type 1 (insulin-dependent) diabetic and 54% of the Type 2 (non-insulin-dependent) diabetic subjects. This result for Type 1 diabetic patients was significantly different from the normal subjects, while that for Type 2 patients was intermediate between the two. In contrast to a previous report, there was no significant association of acetylator status with peripheral neuropathy in subjects with either Type 1 or Type 2 diabetes. Acetylator status could be a genetic marker for Type 1 diabetes, but the increased proportion of fast acetylators in both groups suggested the possibility of an artefact due to high glucose levels. The rate of acetylation of sulphadimidine was significantly greater in both fast and slow acetylators with diabetes compared with normal subjects and there was a significant association between high plasma glucose and acetylator status. Prospective studies will be necessary to confirm whether acetylator status is a true genetic marker for diabetes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.